CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF
申请人:PFIZER INC.
公开号:US20130129753A1
公开(公告)日:2013-05-23
The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.
本发明涉及细胞毒性五肽,其抗体药物偶联物,以及使用它们治疗癌症的方法。
HETEROCYCLIC COMPOUNDS AND USES THEREOF
申请人:SINGH Juswinder
公开号:US20080300268A1
公开(公告)日:2008-12-04
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
本发明提供了化合物、药学上可接受的组合物以及使用它们的方法。
TUBULYSIN ANALOGS AND METHODS OF MAKING AND USE
申请人:Bristol-Myers Squibb Company
公开号:US20160130299A1
公开(公告)日:2016-05-12
Tubulysin analogs of the formula (I)
where R
1
, R
2
R
3
, R
4
, R
5
, R
6
, R
7
, and Y are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments
申请人:NEUROVANCE, Inc.
公开号:US20140303207A1
公开(公告)日:2014-10-09
The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
[EN] COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR L'INHIBITION DE L'ACTIVITÉ DE DÉVELOPPEMENT D'ECTODERME EMBRYONNAIRE DE PROTÉINE ET DE TRAITEMENT D'UNE MALADIE
申请人:EXO THERAPEUTICS INC
公开号:WO2021195183A1
公开(公告)日:2021-09-30
The invention provides compounds that are inhibitors of the protein embryonic ectoderm development (EED), pharmaceutical compositions, their use in modulating the activity of EED, and their use in the treatment of medical disorders, such as cancer. The invention further provides methods of treating medical disorders, such as cancer, and covalently modifying and/or modulating the activity of EED, using an agent that reacts with, and forms a covalent bond to, cysteine324 of EED.